The European Patent Office (EPO) has published a new, expanding “Fighting coronavirus” platform designed to help researchers and decision-makers benefit from patent information in their fight against the new coronavirus.
This important patent decision comes from the UK Supreme with a holding that Regeneron’s patents are invalid for insufficiency of the disclosure.